[go: up one dir, main page]

BRPI1015472A2 - métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central - Google Patents

métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central

Info

Publication number
BRPI1015472A2
BRPI1015472A2 BRPI1015472A BRPI1015472A BRPI1015472A2 BR PI1015472 A2 BRPI1015472 A2 BR PI1015472A2 BR PI1015472 A BRPI1015472 A BR PI1015472A BR PI1015472 A BRPI1015472 A BR PI1015472A BR PI1015472 A2 BRPI1015472 A2 BR PI1015472A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
methods
nervous system
central nervous
Prior art date
Application number
BRPI1015472A
Other languages
English (en)
Inventor
Gary Lee
Robert Boyd
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of BRPI1015472A2 publication Critical patent/BRPI1015472A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1015472A 2009-04-09 2010-04-09 métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central BRPI1015472A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (1)

Publication Number Publication Date
BRPI1015472A2 true BRPI1015472A2 (pt) 2015-11-24

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015472A BRPI1015472A2 (pt) 2009-04-09 2010-04-09 métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central

Country Status (11)

Country Link
US (1) US8304429B2 (pt)
EP (1) EP2416655B1 (pt)
JP (1) JP5634498B2 (pt)
CN (1) CN102448306B (pt)
AU (1) AU2010233187B2 (pt)
BR (1) BRPI1015472A2 (pt)
CA (1) CA2758187C (pt)
ES (1) ES2505243T3 (pt)
IL (1) IL215584A (pt)
NZ (1) NZ595630A (pt)
WO (1) WO2010118282A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758271C (en) * 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders
DK2490533T3 (en) 2009-10-19 2015-12-07 Amicus Therapeutics Inc NOVEL COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF Lysosomal Storage DISEASES
CN102655747A (zh) 2009-10-19 2012-09-05 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
JP2017502961A (ja) 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
KR20190072521A (ko) * 2016-09-12 2019-06-25 스티븐 호프만 치매를 치료하기 위한 조성물
AR110074A1 (es) * 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CN111819283A (zh) 2018-01-12 2020-10-23 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
SG11202006526YA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243196T1 (de) * 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
CA2611011C (en) * 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
ATE555788T1 (de) * 2006-06-23 2012-05-15 Amicus Therapeutics Inc Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
CA2758271C (en) * 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders

Also Published As

Publication number Publication date
ES2505243T3 (es) 2014-10-09
IL215584A (en) 2016-11-30
AU2010233187A1 (en) 2011-11-03
US20100261753A1 (en) 2010-10-14
CN102448306A (zh) 2012-05-09
US8304429B2 (en) 2012-11-06
NZ595630A (en) 2013-04-26
CA2758187A1 (en) 2010-10-14
CN102448306B (zh) 2014-07-02
CA2758187C (en) 2017-03-07
EP2416655A4 (en) 2012-09-05
JP5634498B2 (ja) 2014-12-03
AU2010233187B2 (en) 2015-10-08
EP2416655A1 (en) 2012-02-15
IL215584A0 (en) 2011-12-29
HK1168005A1 (zh) 2012-12-21
WO2010118282A1 (en) 2010-10-14
JP2012523430A (ja) 2012-10-04
EP2416655B1 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
BRPI1015472A2 (pt) métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
PT2470191E (pt) Métodos e composições para prevenção ou tratamento de doenças oftálmicas
BR112012007950A2 (pt) método para tratar água residual e sistema de tratamento
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0717482A2 (pt) Sistema para o tratamento de uma alimentação de hidrocarboneto
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
PL2464362T3 (pl) Probiotyczny preparat do zapobiegania lub leczenia psich zaburzeń układu pokarmowego
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BR112012000422A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a prevenir tratar ou melhorar doenças do sistema imune
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BRPI1008909A2 (pt) métodos e sistema de tratamento de veia
BRPI1013559A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
BR112014002619A2 (pt) composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
BR112013015870A2 (pt) método para o tratamento de biomassa e sistema
BR112013021984A2 (pt) métodos e sistema de tratamento de poço
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI0909628A2 (pt) compostos de azaindol para o tratamento de distúrbios do sistema nervosos central
BRPI1010517A2 (pt) métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
BR112012033536A2 (pt) sistema de esterilização através de chuveiro e método de utilização
BR112013013898A2 (pt) compostos de pirimidinona para o uso no tratamento de doenças ou condições mediadas por lp-pla2
SMT201700105B (it) Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements